The development of bioeconomy is in the ascendant of a new track. It is also a strategic emerging industry with national key development. The output value of the industry is nearly 5 trillion yuan.
According to the official website of Heilongjiang Provincial Development and Reform Commission, recently, the province issued the “14th five year plan for bioeconomy development in Heilongjiang Province”. According to the newly issued plan, by 2025, the total scale of bioeconomy in the province will reach more than 420 billion yuan, and the proportion of added value in regional GDP will be increased to 10%.
Bioeconomic output value exceeds 5 trillion
great development potential
China’s 14th five year plan and the outline of long-term goals for 2035 propose to promote the integration and innovation of biotechnology and information technology, accelerate the development of biomedicine, biological breeding, biomaterials, bioenergy and other industries, and expand and strengthen the bioeconomy.
Bioeconomy is a new economic form with broad connotation and great potential. The development of bioeconomy is in the ascendant of a new track, and it is also a strategic emerging industry with national key development.
At present, many places in China have issued relevant policies to support the development of bioeconomy, vigorously promoting bioeconomy to become an important growth pole of local economic development and the core support for the development of strategic emerging industries.
bioeconomy covers many fields such as biomedicine, bio agriculture, bio manufacturing and bio environmental protection. It is a strategic emerging industry with innovative vitality, wide coverage and far-reaching impact
According to the report of the research group of the Institute of industrial economics of the Chinese Academy of macroeconomics, at the end of the 13th five year plan, the output value of China’s biomedicine, biological manufacturing, biological breeding, bioenergy and biological environmental protection was nearly 5 trillion yuan, and the main business income of the biological and large health industry exceeded 10 trillion yuan.
net profit of 36 companies has increased for three consecutive years
There are many listed companies with bioeconomy related businesses in the A-share market. Which companies have higher growth?
According to the statistics of securities times · data treasure, according to the calculation of the net profit of the annual report and express report, excluding the companies listed for less than one year, the net profit growth of 20 companies has exceeded 20% in the past three years. This includes two leading companies with a market value of more than 100 billion, namely Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) , Chongqing Zhifei Biological Products Co.Ltd(300122) .
Since this year, the trend of high growth track has dropped significantly, and the overall performance of the above high growth companies is not satisfactory.
According to the statistics of databao, compared with the high point in the year, Zhejiang Xianju Pharmaceutical Co.Ltd(002332) , Autek China Inc(300595) , Zhejiang Jolly Pharmaceutical Co.Ltd(300181) , Changchun High And New Technology Industries (Group) Inc(000661) and other stocks retreated by more than 40%.
From the latest valuation level, half of the companies have a rolling P / E ratio of less than 30 times Shanxi Zhendong Pharmaceutical Co.Ltd(300158) P / E ratio of 4.62 times ranked the lowest. Last year, the company achieved a profit of 2.617 billion yuan, a year-on-year increase of 9 times, mainly due to the sale of Langdi pharmaceutical.
Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) is China’s time-honored “Chinese time-honored brand enterprise”. In the first half of last year, the company completed the Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) clinical trial plan to increase the therapeutic effect of hepatitis B, and actively promoted Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) to treat 6 clinical studies such as chronic hepatitis B liver fibrosis, and carried out 30 research topics such as pharmacology, toxicology, clinical quality standards, etc.
Jafron Biomedical Co.Ltd(300529) specializes in the R & D, production and sales of biomaterials and high-tech medical devices. The self-developed disposable hemoperfusion device, disposable plasma bilirubin adsorber, cytokine adsorption column, hemodialysis powder and blood purification equipment are widely used in the treatment of uremia, poisoning, severe liver disease, multiple organ failure and other fields.
Guangdong Hybribio Biotech Co.Ltd(300639) is a leading enterprise in HPV nucleic acid detection of cervical cancer. STD nucleic acid detection series products have formed a multi-level product matrix of single test, two joint test, three joint test and ten joint test, which fully meets the diverse needs of clinical diagnosis. Gene detection products such as thalassemia, deafness susceptibility gene and broad bean disease have been developed in the prevention and control of birth defects.
